GIPR and neoplasm: Blood glucose, food intake, and major tissues including brown adipose, liver, and spleen weights were similar between RETA and SEMA, yet RETA uniquely reduced adiposity and delayed tumor latency suggesting that targeting a single receptor GLP1R was effective for many physiologic and metabolic benefits, but the additional agonism of GIPR and GPCR by RETA uniquely impacted adiposity, tumor onset, and tumor progression.